+54 9 11 5565 6846 / info@bamsite.com.ar / Arenales 981, Buenos Aires, Argentina

From Argentina, to the world.

Driving innovation in Clinical Research

Team of clinical trials experts providing accurate data and high-quality care.

20+ years of experience

We work with the most important regulatory authorities in the world: ANMAT (Argentina), FDA (United States) and EMA (Europe).

Find out how to be part of our studies here.

30+ clinical trials running

Patient recruitment has a limited time window. Apply today to be ready as soon as the next available trial begins.

FDA, EMA & ANMAT

Advanced-stage studies that have already passed all safety tests and now compare efficacy to match or exceed the best treatment currently available.

Sponsors & CROs

Our high standards lead us to success.

Taking part in a clinical trial is a process that requires the highest level of responsibility and care. Each study is designed under strict international protocols to ensure patient safety and the scientific validity of the results. Before starting, all potential risks and benefits are carefully evaluated, and every step follows the guidelines set by regulatory authorities such as ANMAT, FDA and EMA, ensuring compliance with the highest quality standards.

The experience and professionalism of the team conducting the study are key factors. At our institution, we have a group of specialized physicians and healthcare professionals with extensive clinical research experience. Every team member is trained to safeguard patient safety, well-being and rights, working with dedication and commitment at every stage of the trial.

92 %

Completed projects

71 %

Exceeded objectives

Completed studies

Management and professionalism, which allow us to increase the speed and consistency of results:

  • SPONSOR: ROCHE
  • STUDY: LUCERNE
  • CONDITION: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
  • DRUG: FARICIMAB
  • STATUS: COMPLETED
  • ENROLLMENT TARGET: 5 PATIENTS
  • FULFILLED: 5 PATIENTS
  • SPONSOR: ROCHE
  • STUDY: AVONELLE
  • CONDITION: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
  • DRUG: FARICIMAB (LUCERNE extension)
  • STATUS: ONGOING
  • ENROLLMENT TARGET: 4 PATIENTS
  • FULFILLED: ✅ 4 PATIENTS
  • SPONSOR: OPTHEA
  • STUDY: COAST
  • CONDITION: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
  • DRUG: OPT-302
  • STATUS: ONGOING / RECRUITMENT OPEN
  • ENROLLMENT TARGET: 5 PATIENTS
  • FULFILLED: ✅ 4 PATIENTS
  • SPONSOR: ROCHE
  • STUDY: SANDCAT
  • CONDITION: UVEITIC MACULAR EDEMA
  • DRUG: RO07200220
  • STATUS: ONGOING / RECRUITMENT OPEN
  • TARGET: 5 PATIENTS
  • SPONSOR: ROCHE
  • STUDY: ALLUVIUM
  • CONDITION: DIABETIC MACULAR EDEMA
  • DRUG: RO7200220
  • STATUS: ONGOING
  • ENROLLMENT TARGET: 5 PATIENTS
  • EXCEEDED: ✅ 10 PATIENTS
  • SPONSOR: OCUDYNE, INC
  • STUDY: OC-1901AR
  • CONDITION: AGE-RELATED MACULAR DEGENERATION
  • DRUG: SURGICAL INTERVENTION PROCEDURES
  • STATUS: ONGOING / RECRUITMENT OPEN
  • EXCEEDED: ✅ 4 PATIENTS
  • SPONSOR: GSK
  • STUDY: B WELL 1 / 202009
  • CONDITION: Chronic hepatitis B treated with nucleoside/nucleotide analogs
  • DRUG:
  • STATUS: Enrolling
  • ENROLLMENT TARGET:
  • OVERCOME: 3
  • SPONSOR: Eli Lilly
  • STUDY: J3L-MC-EZEF / ACCLAIM-Lp(a)
  • CONDITION: Atherosclerotic cardiovascular disease
  • DRUG:
  • STATUS: Enrolling
  • ENROLLMENT TARGET: 4
  • OVERCOME: 5
  • SPONSOR: Eli Lilly
  • STUDY: ACHIEVE-4 / J2A-MC-GZGS
  • CONDITION: Type 2 diabetes and obesity or overweight, with increased cardiovascular risk
  • DRUG: LY3502970 once daily compared to insulin glargine
  • STATUS: Enrollment closed
  • ENROLLMENT TARGET: Expected inclusion
  • OVERCOME: 11
  • SPONSOR: ALVOTECH
  • STUDY: AV706-GL-C01
  • CONDITION: WET NEOVASCULAR MACULAR DEGENERATION
  • DRUG: AVT06 compared to EU-EYLEA
  • STATUS: ONGOING
  • ENROLLMENT TARGET: 3 PATIENTS
  • EXCEEDED: ✅ 5 PATIENTS
  • SPONSOR: IVERIC BIO
  • STUDY: ISEE_2008
  • CONDITION: GEOGRAPHIC ATROPHY
  • DRUG: ZIMURA
  • STATUS: COMPLETED
  • ENROLLMENT TARGET: 3 PATIENTS
  • FULFILLED: ✅ 3 PATIENTS
  • SPONSOR: Roche
  • STUDY: SATRAGO / GP44467
  • CONDITION: Thyroid Eye Disease
  • DRUG:
  • STATUS: Enrolling
  • ENROLLMENT TARGET:
  • INCLUDED: 2
  • SPONSOR: Novo Nordisk
  • STUDY: REIMAGINE 4
  • CONDITION: Efficacy and Safety of cagrilintide and semaglutide 2.4 mg
  • DRUG:
  • STATUS: Enrolling
  • ENROLLMENT TARGET:
  • OVERCOME: 15
  • SPONSOR: OTX
  • STUDY: OTX-TKI-2023-AMD-301
  • CONDITION: Age-related neovascular macular degeneration
  • DRUG:
  • STATUS: Enrolling
  • ENROLLMENT TARGET:
  • INCLUDED:
  • SPONSOR: SANTEN
  • STUDY: LUMINA
  • CONDITION: ACTIVE INFECTIOUS POSTERIOR SEGMENT UVEITIS
  • DRUG: 440 µg of DE-109
  • STATUS: COMPLETED
  • ENROLLMENT TARGET: 3 PATIENTS
  • EXCEEDED: ✅ 6 PATIENTS
  • SPONSOR: NOVARTIS
  • STUDY: KESTREL
  • CONDITION: DIABETIC MACULAR EDEMA
  • DRUG: BROLUCIZUMAB versus AFLIBERCEPT
  • STATUS: COMPLETED
  • ENROLLMENT TARGET: 10 PATIENTS
  • EXCEEDED: ✅ 24 PATIENTS
  • SPONSOR: APELLIS
  • STUDY: APL-303
  • CONDITION: GEOGRAPHIC ATROPHY SECONDARY TO AMD
  • DRUG: PEGCETACOPLAN
  • STATUS: COMPLETED
  • ENROLLMENT TARGET: 6 PATIENTS
  • EXCEEDED: ✅ 11 PATIENTS
  • SPONSOR: APELLIS
  • STUDY: APL2-305-GALE
  • CONDITION: GEOGRAPHIC ATROPHY SECONDARY TO AMD
  • DRUG: PEGCETACOPLAN (APL-303 Extension)
  • STATUS: ONGOING
  • ENROLLMENT TARGET: 6 PATIENTS
  • EXCEEDED: ✅ 9 PATIENTS
  • SPONSOR: ALVOTECH
  • STUDY: AV706-GL-C01
  • CONDITION: WET NEOVASCULAR MACULAR DEGENERATION
  • DRUG: AVT06 compared to EU-EYLEA
  • STATUS: ONGOING
  • ENROLLMENT TARGET: 3 PATIENTS
  • EXCEEDED: ✅ 5 PATIENTS
  • SPONSOR: NOVARTIS
  • STUDY: CONDOR
  • CONDITION: BROLUCIZUMAB 6 mg compared to LASER Photocoagulation
  • DRUG: BROLUCIZUMAB 6 mg
  • STATUS: ONGOING
  • ENROLLMENT TARGET: 10 PATIENTS
  • EXCEEDED: ✅ 11 PATIENTS
  • SPONSOR: ROCHE
  • STUDY: BALATON
  • CONDITION: MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION
  • DRUG: FARICIMAB
  • STATUS: COMPLETED
  • ENROLLMENT TARGET: 4 PATIENTS
  • EXCEEDED: ✅ 8 PATIENTS
  • SPONSOR: ROCHE
  • STUDY: COMINO
  • CONDITION: MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION
  • DRUG: FARICIMAB
  • STATUS: COMPLETED
  • ENROLLMENT TARGET: 4 PATIENTS
  • EXCEEDED: ✅ 13 PATIENTS
  • SPONSOR: ROCHE
  • STUDY: BARDENAS
  • CONDITION: DIABETIC MACULAR EDEMA
  • DRUG: RO7200220 in combination with RANIBIZUMAB
  • STATUS: ONGOING
  • ENROLLMENT TARGET: 5 PATIENTS
  • EXCEEDED: ✅ 6 PATIENTS

Sponsors & CROs

Contact

These are our contact channels.
We will be in touch with you very soon!


981 Arenales, 4th Floor, Buenos Aires, Argentina

info@bamsite.com.ar

+54 9 11 5565 6846